Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07143448
PHASE1

A Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in Adults

Sponsor: 35Pharma Inc

View on ClinicalTrials.gov

Summary

Phase 1b Study of HS235 Assessing the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of the Activin Signaling Inhibitor HS235 Added to Background Treatment in Adults with Pulmonary Arterial Hypertension (PAH)

Official title: Phase Ib, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study Assessing the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of HS235 Added to Background Treatment in Adults With PAH

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

40

Start Date

2025-10

Completion Date

2028-01

Last Updated

2025-08-27

Healthy Volunteers

No

Interventions

BIOLOGICAL

HS235

Subcutaneous Injection

OTHER

Placebo

Subcutaneous Injection